RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial
2024年12月21日 · Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177Lu-RAD202 in Breast and Gastric Cancers The Phase 1 First-In-Human …
All News - Pipelinereview
4 天之前 · CHENGDU, China I January 20, 2025 I Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) has received marketing authorization in China from National Medical …
Arrowhead Pharmaceuticals Announces Acceptance of New Drug …
6 天之前 · PASADENA, CA, USA I January 17, 2025 I Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has …
PipelineReview.com. Biopharmaceutical News & Clinical Trials
Get the latest biopharma news, clinical trial updates, and industry insights at PipelineReview.com. Discover innovative therapies and regulatory news.
Sumitomo Pharma America Announces U.S. FDA Approval of …
2024年12月23日 · – GEMTESA® is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH – …
Small Molecules - Pipelinereview
2025年1月8日 · Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone First and only BTK …
Lilly's mirikizumab is first and only IL23p19 antagonist to report …
2024年10月28日 · At three years, over 80% of patients with moderately to severely active UC who were in remission with mirikizumab sustained long-term remission and relief from disruptive …
Cadherin 17-Targeted Novel Drug Modalities: a Target and …
BARCELONA, Spain I May 20, 2022 I La Merie Publishing released today its newest report entitled “ Cadherin 17: A target opportunity to develop effector-enhanced drug modalities ”. …
InnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor …
BEIJING, China I January 16, 2024 I InnoCare Pharma (HKEX: 09969; SSE: 688428), a commercial-stage biotech company, announced today that the U.S. Food and Drug …
All News - Pipelinereview
2025年1月13日 · Meaningful tumor shrinkage observed in five out of 10 patients with partial and minor responses and 90% disease control rate in patients with salivary gland cancers Phase …